Login to Your Account

Supports Use Only for 18-49 ages

Panel: FluBlok Safety, Efficacy Data Insufficient for All Adults

By Donna Young

Friday, November 20, 2009
BETHESDA, Md. - Protein Science Inc.'s goal of being the first company in the U.S. to gain approval of a cell-based flu vaccine may have been dashed Thursday after an FDA panel said FluBlok's safety data were insufficient and the efficacy data would only support approval in adults 18 to 49 years, but not older patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription